Nov 29, 2006|
FMCG Midcaps: 2QFY07 review
FMCG midcap companies' results for the September quarter have been stronger in comparison to the large caps for the same quarter. Today, we bring you an analysis of the aggregate performance of 4 mid-cap FMCG companies. The analysis comprises of Marico, Colgate, Godrej Consumers (GCPL) and GSK Consumers.
(The financials are of Marico, Colgate, GSK Consumers and Godrej Consumer Products)
|Operating profit (EBDITA)
|Operating profit margin (%)
|Profit before tax
|Profit after tax
|Net profit margin (%)
The consolidated topline (4 companies combined) grew by over 27% YoY, faster than the topline growth of the larger peers. Increased distribution, wider coverage and lower priced category focus drove the high volumes growth for the quarter. The non-food FMCG sales, which had started recovering from 1 % slump in 2003 to grow at 3% and 5 % in 2004 and 2005, respectively, have moved into the fast track. And this is reflected from growth across the key categories like toothpaste, soaps and shampoos amongst others.
While, Marico's flagship brand, Parachute Coconut Oil, continued its good run as seen over the last few quarters, Colgate registered a 15% YoY growth in the topline driven by sales across its product categories. Strong sales performance of Horlicks, Boost and other products led to a 16.5% YoY growth in the GSK Consumers' topline in the quarter. Its flagship brand 'Horlicks' witnessed double-digit growth driven by new advertising, packaging innovation and effective consumer promotions.
GCPL continued to deliver encouraging growth across all its categories. Toilet soaps sales grew 19% YoY in value terms led by growth in both popular and sub popular categories. Inspite of the 5% to 8% price hike taken on its toilet soaps in the quarter, GCPL outperformed (18.7%) the industry growth (12.8%) yet again. The spending habits of urban consumers on foods and non-foods were about the same while in rural areas, people purchased more of non-food items such as home and personal care products.
Not only has there been higher value growth on the back of price hikes undertaken by various companies this year, but even volumes have increased as more people at the lower end of the market are switching to branded products. And the good news is that the growth will be sustainable.
The expenses of the 4 mid-caps under consideration increased at lower pace than sales, which resulted in operating profits expansion of 43% YoY. Though Marico and Colgate witnessed decline in raw material prices (as a % of sales), GSK and GCPL's margins were under pressure due to higher raw material costs. The advertising costs were more or less stable as not many new products were launched in the quarter. The other expenses also witnessed a decline as a % of sales. The companies had increased the prices of the final products to offset the input pressure. However, going forward, not all companies may be able to pass on the price hike to the customers as fear of losing market share may pop up. Hence, adding new value added products and increasing the volume is likely to be more challenging than before.
The consolidated net profits (including extraordinary items) grew by 7.4% YoY in this quarter, which is lower than the large peers. The main reason for this is the higher interest cost. Marico and GPCL both faced higher interest costs due to their expansion plans. However excluding the extraordinaries, the bottomline has grown by a whopping 62% YoY. All the above factors, coupled with a considerable increase in other income, resulted in a PAT growth for mid-cap FMCG companies. Also aiding bottomline growth was a lower tax outgo, which reduced as a percentage of PBT by 790 basis points. Mid-cap companies have set up their plants in tax havens like Baddi in Himachal Pradesh, which provide them with tax holidays for several years.
Of the 4 companies, Colgate clearly stole the show with its bottomline bloating by a huge 47% YoY, followed by Marico with a 34% YoY growth.
What to expect?
The good performance of the mid-cap FMCG companies over the last few quarters have helped them close the valuation gap with their larger peers (in some cases, even higher than their peers). The smaller FMCG companies have the potential to explore the untapped markets. Acceleration in rural growth, better distribution network, shift in consumer preference will continue to be the growth factors. We believe that selective mid-cap FMCG companies are good investment options from a long-term perspective as their commanding valuations leave little upside from a near term perspective.
More Views on News
Jun 10, 2017
Forty Indian investing gurus, as worthy of imitation as the legendary Peter Lynch, can help you get rich in the stock market.
Aug 18, 2017
Buying the index now will hardly help make money in stocks even in ten years.
Aug 18, 2017
Donald J Trump, a wrasslin' fan, took a 'Holy Sh*t!' blow on Tuesday.
Aug 17, 2017
PersonalFN simplifies the mutual fund account statement for you.
Aug 17, 2017
A small-cap Indian company with high-return potential and blue-chip-like stability is set to supplant the Chinese players in this niche segment.
More Views on News
Aug 7, 2017
The data tells us quite a different story from the one the government is trying to project.
Aug 10, 2017
Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.
Aug 8, 2017
Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...
Aug 12, 2017
The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.
Aug 7, 2017
Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...
Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement. LEGAL DISCLAIMER:
Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here
. The performance data quoted represents past performance and does not guarantee future results.SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.
Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: email@example.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407